ARIAD Pharmaceuticals (ARIA)
ARIAD Pharmaceuticals Revenue Growth: 44.64%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ARIA Revenue Growth Rankings
| Overall | 90th percentile | 403 of 4358 |
| Sector | 83rd percentile | 76 of 456 in Healthcare |
| Industry | 69th percentile | 38 of 126 in Biotechnology |
ARIA Revenue Growth Range, Past 5 Years
| Minimum | -99.96% | Jun 2011 |
| Maximum | 8260% | Jun 2010 |
| Average | 629.7% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ARIA related companies
ARIA News
$ARIA will be hard to figure. We all know if 6/4 ASCO presentation is (+) stock will pop, but don't know if gen public has alrdy digested...
about 17 hours ago by nick159
about 17 hours ago by nick159
NEW POST: NEXT WEEK WILL BE OFF THE CHART HUGE http://stks.co/3zsj $AAPL, $SPX, $ARIA, $IBB, $QQQ
about a day ago by upsidetrader
about a day ago by upsidetrader
shouldn't insiders be holding if they had confidence in ASCO? never seen this much selling in my life lol http://stks.co/3zEF $ARIA
about 2 days ago by johnkelly
about 2 days ago by johnkelly
http://stks.co/3xkr wow got even MORE $ARIA insider selling monday! insiders keep selling, investors keep buying lol
about 4 days ago by johnkelly
about 4 days ago by johnkelly
@RickPalmer907 @kokoluck $ARNA I meant to mention that if you check out $VVUS and $ARIA today, they had large, 4 p.m. double trades
about 6 days ago by SlownSteady
about 6 days ago by SlownSteady
$ARIA, that's right baby, climb! i need u high so i can short at peak levelz before the 4th!
about 6 days ago by johnkelly
about 6 days ago by johnkelly
$ARIA insiderz just keep selling while investorz keep buying, pretty hilarious...
about 6 days ago by johnkelly
about 6 days ago by johnkelly
$ARIA Mentioned more than normal on StockTwits - Currently at 3 x average daily social activity
about 10 days ago by TradeIdeasQuant
about 10 days ago by TradeIdeasQuant
machines playing games in $ARIA trying to stop out peeps on the open
about 10 days ago by harmongreg
about 10 days ago by harmongreg
ASCO '12 abstract: A pivotal phase II trial of ponatinib. $ARIA presents on Monday, Jun 4. http://stks.co/3rnm
about 10 days ago by abubnic
about 10 days ago by abubnic
$ARIA http://stks.co/3rmH Hit a new 52 week high and held up very well when the nasdaq was tanking. Long setup.
about 10 days ago by ACInvestorBlog
about 10 days ago by ACInvestorBlog
Medivation, Ariad Pharmaceuticals Among Stocks Setting 52-Week Highs Wednesday
May 16, 4:56PM Fox Business
May 16, 4:56PM Fox Business
$ARIA nuthin but insider selling since inception. waitin till $18 than shortin this thru ASCO>
about 11 days ago by johnkelly
about 11 days ago by johnkelly
UPDATE: Jefferies Raises PT to $18 on ARIAD Pharmaceuticals; Regulatory Catalysts
May 10, 8:40AM Benzinga
May 10, 8:40AM Benzinga
ARIAD to Present at Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 7:35AM Business Wire
May 10, 7:35AM Business Wire
ARIAD Reports First Quarter 2012 Financial Results and Development Progress
May 09, 7:35AM Business Wire
May 09, 7:35AM Business Wire
ARIAD To Present at the Deutsche Bank 37th Annual Health Care Conference
Apr 30, 7:35AM Business Wire
Apr 30, 7:35AM Business Wire
ARIAD to Webcast Conference Call on First Quarter 2012 Financial Results
Apr 25, 7:35AM Business Wire
Apr 25, 7:35AM Business Wire
UPDATE - UBS Initiates Coverage on Ariad Pharma (ARIA) with a Buy; Ponatinib Can Be A Billion Dollar Drug
Apr 12, 11:04AM Street Insider
Apr 12, 11:04AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ARIA | 16.77 | -0.08 | -0.47% | 2.665B |
| ARI | 15.89 | -0.12 | -0.75% | 326.70M |
| ARGN | 12.21 | -0.32 | -2.55% | 352.26M |
| ARG | 87.77 | -0.96 | -1.08% | 6.702B |
| AREX | 28.34 | -0.15 | -0.53% | 944.01M |
| ARE | 69.83 | -0.69 | -0.98% | 4.332B |
| ARDNA | 81.80 | +0.80 | +0.99% | 251.13M |
| ANV | 27.47 | -0.20 | -0.72% | 2.463B |
| ANTP | 2.460 | -0.00 | -0.04% | 5.880M |
| ANTH | 1.85 | -0.06 | -3.14% | 75.83M |
